A trial looking at atezolizumab for people with head and neck cancer
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
Cancer type:
Status:
Phase:
- mouth (oral cavity)
- oropharynx
- hypopharynx
- larynx
It is for people who have completed initial treatment for their head and neck cancer and have a high risk of the cancer coming back or getting worse.
More about this trial
- surgery
- radiotherapy
- chemotherapy and radiotherapy (chemoradiotherapy)
- atezolizumab
- dummy drug (placebo)
Who can enter
- you have advanced squamous cell carcinoma (SCC) of the head and neck - the oral cavity, oropharynx, larynx, or hypopharynx
- your cancer has been tested for the human papilloma virus (HPV)
- you have finished the main treatment for head and neck cancer
- your cancer stayed the same, got better or disappeared after the main treatment
- you have had scans of your chest and tummy (abdomen) in the last month and these scans showed that you don’t have cancer outside the head and neck area.
- you are well enough to carry out your normal activities apart from heavy physical work (performance status of 0 or 1)
- you have satisfactory blood test results
- are at least 18 years old
- if you are a woman, you are willing to use reliable contraception during treatment and for 5 months afterwards if there is any possibility that you could become pregnant
- your cancer started in the nasopharynx or paranasal sinuses
- your cancer has spread to other parts of your body
- you have had surgery or radiotherapy on its own as the main treatment for your cancer
- your cancer got worse (progressed) during treatment
- you have had treatment with atezolizumab or any other similar drug
- have high levels of calcium in your body that isn’t controlled
- have an autoimmune disease, unless it is a thyroid problem that is controlled with medication, type 1 diabetes, a condition where white patches develop on the skin (vitiligo) or other skin conditions called eczema and psoriasis
- have heart problems such as angina that isn’t stable, an abnormal heart rhythm (arrhythmia) or you have had a heart attack in the last 3 months
- have taken drugs that damp down your immune system (immunosuppressants) such as steroids in the past 2 weeks, unless it was a very small dose
- have had treatment with drugs that have an effect on the immune system such as interferon in the last month
- have active tuberculosis
- have HIV
- have hepatitis B or hepatitis C
- have had an organ or stem cell transplant from a donor
- have had a live vaccine in the last month, or you need to have a live vaccine within 5 months of your last atezolizumab treatment
- are sensitive to atezolizumab or anything it contains
- are pregnant or breastfeeding
Trial design
- atezolizumab
- dummy drug
- every 3 weeks during treatment
- a month after finishing treatment
- then every 3 months
- look for certain substances (biomarkers) that can help to tell how well the treatment works
- find out what happens to atezolizumab in your body
- look for certain substances (biomarkers)
- check whether your cancer has the human papilloma virus (HPV)
Hospital visits
Side effects
- tiredness (fatigue) and lack of energy
- pain in your joints, muscles and bones
- loss of appetite
- loose or watery stools (diarrhoea)
- shortness of breath
- cough
- skin rash and itchy skin
- feeling or being sick
- high temperature (fever)
- infection of the bladder (urinary tract infection)
Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Chief Investigator
Professor Kevin Harrington
Supported by
Roche
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040